Evidence map›Paper›PMID 42840118›Full record

Observational studyFrontiers in public health2026

COVID-19 outcomes in patients with inflammatory rheumatic diseases: associations with disease subtypes, treatments, and vaccination status.

Feyza Ak, Zeynep Kaya

Abstract readObservational Study
In one paragraph

Observational study in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Feyza AkDivision of Rheumatology, Department of Internal Medicine, Istanbul Bezmi Alem University Hospital, Istanbul, Türkiye.
Zeynep KayaDivision of Rheumatology, Department of Internal Medicine, Istanbul Training and Research Hospital, Istanbul, Türkiye.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Patients with inflammatory rheumatic diseases (IRDs) may be at increased risk for adverse COVID-19 outcomes because of immune dysregulation, comorbidities, and immunomodulatory treatments. However, the effects of specific rheumatic disease subsets, treatment patterns, and vaccine types remain incompletely understood. Objective: To evaluate clinical characteristics and factors associated with COVID-19 infection and hospitalization among patients with IRDs. Methods: This retrospective observational cohort study included 1,024 adult patients with IRDs followed between March 2020 and January 2023. Demographic characteristics, rheumatic disease subtypes, treatments, vaccination status, COVID-19 infection, hospitalization, radiologic findings, and recovery duration were analyzed. Results: Among all patients, 347 (33.9%) developed COVID-19 infection. Patients with COVID-19 were younger than those without COVID-19 (49.1 ± 13.4 vs. 51.5 ± 14.5 years, Conclusion: Older age, pulmonary comorbidity, longer disease duration, and radiologic involvement were associated with COVID-19-related hospitalization in IRDs. In contrast, FMF, colchicine use, and BNT162b2 vaccination were associated with lower hospitalization rates.

Indexed as

COVID-19COVID-19 VaccinesRheumatic DiseasesVaccinationAdultAgedBNT162 VaccineComorbidityFemaleHospitalizationHumansMaleMiddle AgedRetrospective StudiesSARS-CoV-2BNT162 VaccineCOVID-19 VaccinesBNT162b2CoronaVacCOVID-19inflammatory rheumatic diseasesvaccination

Identifiers

PMID42840118
PMCPMC13638528

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.